Abbott has launched an effort to replace some of its FreeStyle Libre 3 continuous glucose monitors—following reports of ...

The correction relates to around three million sensors used in Abbott’s FreeStyle Libre 3 and Libre 3 Plus CGMs in the US.

Abbott has initiated a medical device correction for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors ...

(MENAFN- PR Newswire) Now cleared in the U.S., Abbott's FreeStyle Libre 2 app helps people manage diabetes right from their iPhone. The app creates a comprehensive, digital experience for FreeStyle ...

AbbottABT announced the availability of FreeStyle LibreLink app in Europe for use in smartphones(both iPhone and Android). Notably, diabetes patients using the ...

Abbott issued a medical device correction for some of its glucose sensors after internal testing found that some sensors may ...

MISSISSAUGA, Ontario, Oct. 4, 2018 /CNW/ -- Abbott (NYSE: ABT) announced today the company has received the Health Canada license of its FreeStyle LibreLink mobile app for use with compatible iOS ...

The Food and Drug Administration (FDA) has cleared the FreeStyle ® Libre 2 iOS App for use with the FreeStyle Libre 2 14-day glucose sensors in individuals 4 years of age and older with diabetes. The ...

Nearly two years after going live in Europe, the latest version of Abbott’s FreeStyle Libre continuous glucose monitor is ready to make its stateside debut. The FDA cleared the FreeStyle Libre 3 ...

MISSISSAUGA, ON, July 8, 2025 /CNW/ -- Abbott (NYSE: ABT) today announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle Libre 3 Plus * sensor, is now ...

Abbott ABT announced the availability of FreeStyle LibreLink app in Europe for use in smartphones(both iPhone and Android). Notably, diabetes patients using the ...